Shandong Lukang Pharmaceutical (SHA:600789) received approval from China's National Medical Products Administration for the marketing of lenvatinib mesylate as a chemical active pharmaceutical ingredient, according to a Shanghai bourse filing on Thursday.
The drug is used as a treatment for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.
The Chinese pharmaceutical company's shares rose 2% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.